Sugi Predict

Sugi Predict / Compounds / SCHEMBL427255

SCHEMBL427255

SCHEMBL427255

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](OP(=O)(O)OC[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)[C@H]1O

nearest known ligand 0.93

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RNASEL Q05823 11/20 0.93
▸ P2RY2 P41231 2/20 0.69
▸ DNPH1 O43598 1/20 0.69
▸ PRKAB2 O43741 1/20 0.69
▸ TRPM2 O94759 1/20 0.69
▸ LDHA P00338 1/20 0.69
▸ ADRB2 P07550 1/20 0.69
▸ FBP1 P09467 1/20 0.69
▸ SRC P12931 1/20 0.69
▸ ADORA1 P30542 1/20 0.69
▸ P2RY1 P47900 1/20 0.69
▸ PRKAG1 P54619 1/20 0.69
▸ PRKAA2 P54646 1/20 0.69
▸ PDE4D Q08499 1/20 0.69
▸ KCNH2 Q12809 1/20 0.69
▸ PRKAA1 Q13131 1/20 0.69
▸ PDE3A Q14432 1/20 0.69
▸ SMN1; SMN2 Q16637 1/20 0.69
▸ TAS1R3 Q7RTX0 1/20 0.69
▸ TAS1R1 Q7RTX1 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8611259 0.96 RNASEL (0.88) RNASELP2RY2DNPH1PRKAB2TRPM2
SCHEMBL30689044 0.96 RNASEL (0.88) RNASELP2RY2DNPH1PRKAB2TRPM2
SCHEMBL8613078 0.96 RNASEL (0.88) RNASELP2RY2DNPH1PRKAB2TRPM2
SCHEMBL29581821 0.96 RNASEL (0.88) RNASELP2RY2DNPH1PRKAB2TRPM2
SCHEMBL25401608 0.95 RNASEL (0.87) RNASELP2RY2DNPH1PRKAB2TRPM2
Adenosine Phosphate SCHEMBL15532261 0.94 RNASEL (0.87) RNASELP2RY2DNPH1PRKAB2TRPM2
SCHEMBL22765783 0.93 RNASEL (0.82) RNASELP2RY2ADORA1
SCHEMBL29365708 0.93 RNASEL (0.82) RNASELP2RY2ADORA1
Adenosine Triphosphate SCHEMBL29515512 0.92 RNASEL (0.84) RNASELP2RY2DNPH1PRKAB2TRPM2
SCHEMBL29373108 0.91 RNASEL (0.90) RNASEL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216364-A1 STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT ENYO PHARMA (FR) 2024-07-04 — — US claimed
EP-4329761-A1 STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT ENYO Pharma (FR) 2024-03-06 — — EP claimed
EP-3218512-B1 A METHOD OF SCREENING FOR MODULATION OF CELL SIGNALLING PATHWAYS CAMBRIDGE ENTPR LTD (GB) 2019-09-04 — — EP claimed
EP-0685234-B1 DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER NIPPON SHINYAKU CO LTD (JP) 2000-05-10 — — EP claimed
US-5705188-A LIPID MIXTURE, ANTITUMOR AGENTS NIPPON SHINYAKU COMPANY, LTD. (JP) 1998-01-06 — — US claimed
EP-0685234-A1 DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER NIPPON SHINYAKU COMPANY, LIMITED (JP) 1995-12-06 — — EP claimed
US-12030861-B1 L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof ENYO PHARMA (FR) 2024-07-09 — — US disclosed
US-20240216364-A1 STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT ENYO PHARMA (FR) 2024-07-04 — — US disclosed
US-12018285-B2 Integration sites in CHO cells BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-06-25 — — US disclosed
CN-118103512-A Selectable markers for eukaryotic expression systems 上海臻格生物技术有限公司 2024-05-28 — — CN disclosed
CN-114302743-B HLA-DR/CII peptide complexes for the treatment of arthritis 弗劳恩霍夫应用研究促进协会 2024-05-14 — — CN disclosed
CN-117986272-A Condensed polycyclic compounds, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-05-07 — — CN disclosed
CN-117683042-A Fused tetracyclic compound, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2024-03-12 — — CN disclosed
EP-0685234-B1 DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER NIPPON SHINYAKU CO LTD (JP) 2000-05-10 — — EP disclosed
US-5705188-A LIPID MIXTURE, ANTITUMOR AGENTS NIPPON SHINYAKU COMPANY, LTD. (JP) 1998-01-06 — — US disclosed
US-5705188-A LIPID MIXTURE, ANTITUMOR AGENTS NIPPON SHINYAKU COMPANY, LTD. (JP) 1998-01-06 — — US disclosed
EP-0685234-A4 DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER. NIPPON SHINYAKU CO LTD (JP) 1997-10-22 — — EP disclosed
EP-0685234-A1 DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER NIPPON SHINYAKU COMPANY, LIMITED (JP) 1995-12-06 — — EP disclosed
EP-0685234-A1 DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER NIPPON SHINYAKU COMPANY, LIMITED (JP) 1995-12-06 — — EP disclosed
WO-1994018987-A1 DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER NIPPON SHINYAKU CO., LTD. (JP) 1994-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216364-A1 STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT TLR3, NR1H4, TLR9 RNASEL 3456/4885P2RY2 175/4885DNPH1 4865/4885
US-12030861-B1 L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof PHYKPL, BCAT2, AADAT RNASEL 3965/4885P2RY2 2600/4885DNPH1 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.